logo

For the Inventor, By the Inventor

Brier, WA, United States of America

Donald B Axworthy

This inventor holds 15 USPTO granted patents. Top assignees: Neorx Corporation, Aletheon Pharmaceuticals, Inc.. Active years: 1994-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donald B Axworthy. Retrieved from https://idiyas.com/inventor/donald-b-axworthy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 93.3

Average Co-Inventor Count = 3.0

ph-index = 10

Forward Citations = 305(Granted Patents)


Company Filing History:

goldMedal13 out of 156 
 
Neorx Corporation
 patents
silverMedal2 out of 3 
 
Aletheon Pharmaceuticals, Inc.
 patents

Years Active: 1994-2006

Loading Chart...
15 patents (USPTO):Explore Patents
1. 7078013 - Pretargeting methods and compounds (2006-07-18),
2. 6908903 - Cluster clearing agents (2005-06-21),
3. 6416738 - Pretargeting methods and compounds (2002-07-09),
4. 6172045 - Cluster clearing agents (2001-01-09),
5. 6075010 - Small molecular weight ligand-hexose containing clearing agents (2000-06-13),
6. 5985826 - Methods of using hepatic-directed compounds in pretargeting strategies (1999-11-16),
7. 5976535 - Pretargeting protocols for the enhanced localization of cytotoxins to (1999-11-02),
8. 5955605 - Biotinidase resistant biotin-DOTA conjugates (1999-09-21),
9. 5914312 - Pretargeting methods and compounds (1999-06-22),
10. 5911969 - Pretargeting protocols for enhanced localization of active agents to (1999-06-15),
11. 5886143 - Hepatic-directed compounds and reagents for preparation thereof (1999-03-23),
12. 5624896 - Clearing agents useful in pretargeting methods (1997-04-29),
13. 5616690 - Hexose derivatized human serum albumin clearing agents (1997-04-01),
14. 5608060 - Biotinidase-resistant biotin-DOTA conjugates (1997-03-04),
15. 5283342 - Biotinylated small molecules (1994-02-01),

Title: The Innovative Contributions of Donald B Axworthy

Introduction

Donald B Axworthy is a notable inventor based in Brier, WA (US), recognized for his significant contributions to the field of biomedical engineering. With a total of 15 patents, he has made remarkable advancements in the delivery of diagnostic and therapeutic agents.

Latest Patents

Among his latest patents, Axworthy has developed methods and compounds related to pretargeted delivery of diagnostic and therapeutic agents. These innovations include methods for radiometal labeling of biotin and improved radiohalogenation of biotin. Additionally, he has explored the use of clearing agents, anti-ligand-targeting moiety conjugates, and target cell retention enhancing moieties. Another significant patent involves Cluster Clearing Agents (CCAs), which are designed to direct the biodistribution of a CCA-containing construct to hepatic clearance, enhancing the efficiency of therapeutic compounds.

Career Highlights

Throughout his career, Axworthy has worked with various companies, including Neorx Corporation and Aletheon Pharmaceuticals, Inc. His work has focused on improving the efficacy of drug delivery systems and enhancing the therapeutic potential of various compounds.

Collaborations

Axworthy has collaborated with esteemed colleagues such as John M Reno and Louis J Theodore, contributing to the advancement of innovative solutions in his field.

Conclusion

Donald B Axworthy's contributions to biomedical engineering through his patents and collaborations have significantly impacted the development of advanced therapeutic delivery systems. His work continues to inspire innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…